News - Global, Mergers & Acquisitions


Popular Filters

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling


The record start to 2014’s pharma M&A has been a welcome boost to a deal market that had been in the…

CancerGlobalInterviewsMergers & AcquisitionsPfizerPharmaceuticalPharmaceutical industryPharmaceutical sciences

Pharmaceutical and life sciences deal volume up 53% in 1st-qtr, sets stage for heightened activity in 2014


Pharmaceutical and life sciences (PLS) merger and acquisition (M&A) volume increased 53.1% in the first…

GlobalMergers & AcquisitionsPharmaceutical

Sustainability of sky-high M&A valuations will be the biggest question for 2014, says new report


The cautious optimism of 2012 turned into a fully fledged biotech boom in 2013, marked by surging company…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Big pharma's need to tap M&A for growth will persist in 2014, while dealmaking landscape becomes more competitive, says EY


Big pharma stayed on the sidelines in the 2013 mergers and acquisitions market despite a continuing need…

GlobalMergers & AcquisitionsPharmaceutical

Pharma M&A deals in 2013 down, but values marginally higher

Pharma M&A deals in 2013 down, but values marginally higher


Merger and acquisition activity in the pharmaceutical, biotechnology and generic drugs sectors continued…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Clinigen acquires oncology support therapy Cardioxane from Novartis


UK-based Clinigen Group (LSE: CLIN) says it has acquired (AIM: CLIN) the oncology support therapy Cardioxane…

CardioxaneClinigen GroupGlobalMergers & AcquisitionsNovartisOncologyPharmaceutical

Health care M&A spending falls nearly 40% in 2012, lowest year on record since 2003; report


In 2012, dealmakers committed $143.3 billion to finance the year's activity in the health care merger,…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Investment in "pharmerging" markets at highest-ever level, according to Freshfields


While global merger and acquisition (M&A) activity involving pharmaceutical companies has fallen to $146…

GlobalMergers & AcquisitionsPharmaceutical

Global generic drug markets will grow to $221 billion by 2016; Espicom


The economic recession has been a double-edged sword for the international generic drugs business. Driven…

GenericsGlobalMarkets & MarketingMergers & AcquisitionsPricing

Global biotechnology market set to exceed $320 billion by 2015, says GIA


The biotechnology industry was adversely affected by the global financial crisis, with several leading…

BiotechnologyGlobalMarkets & MarketingMergers & AcquisitionsResearch

Sanofi to top Pfizer as number one for global pharma sales


French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

Back to top